Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
Background: The GENEVIEVE study compared the pathological complete response (pCR) rate (ypT0/is ypN0/+) in patients with operable human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC) treated with either cabazitaxel or paclitaxel. Methods: GENEVIEVE was a prospective, multicent...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
October 2017
|
| In: |
European journal of cancer
Year: 2017, Volume: 84, Pages: 1-8 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2017.06.037 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1016/j.ejca.2017.06.037 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0959804917311036 
|
| Author Notes: | Sherko Kümmel, Stefan Paepke, Jens Huober, Christian Schem, Michael Untch, Jens Uwe Blohmer, Wolfgang Eiermann, Bernd Gerber, Claus Hanusch, Jörn Hilfrich, Christian Jackisch, Andreas Schneeweiss, Carsten Denkert, Knut Engels, Peter Klare, Peter A. Fasching, Gunter von Minckwitz, Nicole Burchardi, Sibylle Loibl |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1584494301 | ||
| 003 | DE-627 | ||
| 005 | 20240316100543.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 181127s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2017.06.037 |2 doi | |
| 035 | |a (DE-627)1584494301 | ||
| 035 | |a (DE-576)514494301 | ||
| 035 | |a (DE-599)BSZ514494301 | ||
| 035 | |a (OCoLC)1341024450 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kümmel, Sherko |d 1971- |e VerfasserIn |0 (DE-588)122704142 |0 (DE-627)082103372 |0 (DE-576)293388016 |4 aut | |
| 245 | 1 | 0 | |a Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE) |c Sherko Kümmel, Stefan Paepke, Jens Huober, Christian Schem, Michael Untch, Jens Uwe Blohmer, Wolfgang Eiermann, Bernd Gerber, Claus Hanusch, Jörn Hilfrich, Christian Jackisch, Andreas Schneeweiss, Carsten Denkert, Knut Engels, Peter Klare, Peter A. Fasching, Gunter von Minckwitz, Nicole Burchardi, Sibylle Loibl |
| 264 | 1 | |c October 2017 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 27.11.2018 | ||
| 520 | |a Background: The GENEVIEVE study compared the pathological complete response (pCR) rate (ypT0/is ypN0/+) in patients with operable human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC) treated with either cabazitaxel or paclitaxel. Methods: GENEVIEVE was a prospective, multicentre, randomised, open-label, phase II study comparing the efficacy and the safety of four 3-weekly cycles cabazitaxel versus 12 weeks of paclitaxel given as neoadjuvant treatment. Primary end-point was the pCR rate defined as the complete absence of invasive carcinoma on histological examination of the breast irrespective of lymph node involvement (ypT0/is, ypN0/+) after the taxane treatment. Patients could receive an anthracycline-based therapy hereafter. Results: Overall, 333 patients were randomised and started treatment with 74.7% and 83.2% of patients completing treatment in the cabazitaxel and paclitaxel arms, respectively. Patients in cabazitaxel arm had a significantly lower pCR rate compared to the paclitaxel arm (1.2% versus 10.8%; p = 0.001). A total of 42 (25.3%) patients in the cabazitaxel arm and 17 (10.2%) in the paclitaxel arm had at least one serious adverse event (p < 0.001). Dose reductions were observed in 9.6% patients in the cabazitaxel arm compared to 11.4% in the paclitaxel arm (p = 0.721). Main reason for dose reductions was non-haematological toxicities in 3.0% versus 7.8% (p = 0.087), respectively. Conclusions: The GENEVIEVE study showed no short-term effect of cabazitaxel in triple-negative or luminal B/HER2-negative primary BC, while there seemed to be no differences in drug exposure and patient compliance between the two arms. Clinical trials registration ClinicalTrials.gov NCT01779479. | ||
| 650 | 4 | |a Breast cancer | |
| 650 | 4 | |a Cabazitaxel | |
| 650 | 4 | |a Paclitaxel | |
| 650 | 4 | |a Pathological complete response | |
| 700 | 1 | |a Schneeweiss, Andreas |d 1961- |e VerfasserIn |0 (DE-588)109972554 |0 (DE-627)632849630 |0 (DE-576)327251859 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer |d Amsterdam [u.a.] : Elsevier, 1992 |g 84(2017), Seite 1-8 |w (DE-627)266883400 |w (DE-600)1468190-0 |w (DE-576)090954173 |x 1879-0852 |7 nnas |a Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE) |
| 773 | 1 | 8 | |g volume:84 |g year:2017 |g pages:1-8 |g extent:8 |a Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE) |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejca.2017.06.037 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S0959804917311036 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20181127 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 109972554 |a Schneeweiss, Andreas |m 109972554:Schneeweiss, Andreas |d 910000 |d 910400 |e 910000PS109972554 |e 910400PS109972554 |k 0/910000/ |k 1/910000/910400/ |p 12 | ||
| 999 | |a KXP-PPN1584494301 |e 3034157452 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"eki":["1584494301"],"doi":["10.1016/j.ejca.2017.06.037"]},"recId":"1584494301","name":{"displayForm":["Sherko Kümmel, Stefan Paepke, Jens Huober, Christian Schem, Michael Untch, Jens Uwe Blohmer, Wolfgang Eiermann, Bernd Gerber, Claus Hanusch, Jörn Hilfrich, Christian Jackisch, Andreas Schneeweiss, Carsten Denkert, Knut Engels, Peter Klare, Peter A. Fasching, Gunter von Minckwitz, Nicole Burchardi, Sibylle Loibl"]},"relHost":[{"titleAlt":[{"title":"EJC online"}],"disp":"Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)European journal of cancer","corporate":[{"display":"European Organization for Research on Treatment of Cancer","role":"isb"},{"display":"European Association for Cancer Research","role":"isb"},{"display":"European School of Oncology","role":"isb"}],"part":{"year":"2017","text":"84(2017), Seite 1-8","pages":"1-8","volume":"84","extent":"8"},"language":["eng"],"id":{"eki":["266883400"],"zdb":["1468190-0"],"issn":["1879-0852"]},"recId":"266883400","note":["Gesehen am 21.03.24","Ungezählte Beil.: Supplement"],"title":[{"title_sort":"European journal of cancer","title":"European journal of cancer"}],"pubHistory":["28.1992 -"],"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"1992-","publisherPlace":"Amsterdam [u.a.] ; [Erscheinungsort nicht ermittelbar]","publisher":"Elsevier ; Pergamon Press","dateIssuedKey":"1992"}]}],"physDesc":[{"extent":"8 S."}],"language":["eng"],"title":[{"title":"Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)","title_sort":"Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)"}],"person":[{"role":"aut","display":"Kümmel, Sherko","given":"Sherko","family":"Kümmel"},{"role":"aut","family":"Schneeweiss","given":"Andreas","display":"Schneeweiss, Andreas"}],"origin":[{"dateIssuedDisp":"October 2017","dateIssuedKey":"2017"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 27.11.2018"]} | ||
| SRT | |a KUEMMELSHERANDOMISED2017 | ||